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Traditional Chinese Marine Medicine (TCMM) represents one of the medicinal resources for research and development of novel
anticancer drugs. In this study, to investigate the presence of anticancer activity (AA) displayed by cold or hot nature of TCMM,
we analyzed the association relationship and the distribution regularity of TCMMs with different nature (613 TCMMs originated
from 1,091 species of marine organisms) via association rules mining and phylogenetic tree analysis. The screened association
rules were collected from three taxonomy groups: (1) Bacteria superkingdom, Phaeophyceae class, Fucales order, Sargassaceae
family, and Sargassum genus; (2) Viridiplantae kingdom, Streptophyta phylum, Malpighiales class, and Rhizophoraceae family;
(3) Holothuroidea class, Aspidochirotida order, and Holothuria genus. Our analyses showed that TCMMs with closer taxonomic
relationship were more likely to possess anticancer bioactivity.We found that the cluster pattern of marine organisms with reported
AA tended to cluster with cold nature TCMMs. Moreover, TCMMs with salty-cold nature demonstrated properties for softening
hardmass and removing stasis to treat cancers, and species withinMetazoa orViridiplantae kingdomof cold natureweremore likely
to contain AA properties. We propose that TCMMs from these marine groups may enable focused bioprospecting for discovery of
novel anticancer drugs derived from marine bioresources.
1. Introduction
The nature of traditional Chinese medicines (TCMs) can be
classified into three categories (cold, hot, and neutral) that
represent the types of body reactions after the administration
of specific TCM [1, 2].The therapeutic effect of CMs depends
mainly on the nature of the drugs as well as the processes they
regulate to recover the balance between Yin and Yang in the
human body [3, 4]. According to TCM, the rationale for the
correct remedy selection is based upon a correspondingTCM
syndrome (Zheng,证, or pattern) [5]. A patient will present
with a syndrome upon disruption of Yin-Yang balance, which
may be caused either by external and/or internal pathological
factors. This can be regarded as clinical phenotype, such
as cold or hot syndrome [5, 6]. The standard therapeutic
guideline used to treat cold or hot syndrome is to “cure
cold syndrome by medication with hot nature” and to “cure
hot syndrome by medication with cold nature” [5]. This
therapeutic practice has been validated and developed over
thousands of years, and most CMs have thus been labeled
with different nature types as an outcome of this repeated
clinical practice [1]. Recent literature shows that different
biological effects conferred by a specific TCM could serve
as the basis to discriminate cold and hot nature of TCMs
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[7, 8].Thus, conversely, the cold-hot nature of a specific TCM
could potentially serve as clues to its bioactivities including
anticancer properties.
As a vital part of TCMs, Traditional Chinese Marine
Medicine (TCMM) has been used to treat and prevent
diseases for thousands of years, and it is based on a unique
theoretical framework, diagnosis, and treatment [9]. TCMM
appears to be effective in treating various diseases such as
cancers, malaria, diabetes, cardiocerebrovascular diseases,
immunodeficiency diseases, and senile dementia, and there-
fore has become an important medicinal resource for the
research and development of new drugs [10].
Cancer poses serious threat to human health worldwide,
and there have been efforts in screening for compounds pos-
sessing anticancer activity (AA) from TCMMs [17]. Marine
organisms including TCMMs have evolved efficient and
highly potent metabolites that exhibit strong biological activ-
ity at low concentrations to circumvent rapid dilution caused
by their aqueous environment [18], and this confers a poten-
tial advantage over metabolites of terrestrial origin includ-
ing TCMs originating from nonmarine sources. Moreover,
TCMMs contain significant differences fromTCMs of terres-
trial origin including their bioactivity properties, cold andhot
nature [10, 19, 20].Marine organisms have been demonstrated
to be promising source of novel antitumor compounds [18, 21]
and several of the marine families of TCMMs have been
explored and reportedly show anticancer potential [10, 22].
High-throughput screening for novel anticancer drugs
are widely conducted; however it is costly and might yield
chemical hits with low actual clinical efficacy and/or high
toxicity [23]. It has been reported that distinct plant species
yields potent bioactive compounds at higher rates than other
plant species, and most drugs are derived from preexisting
drug-productive families [24]. Clues to drug-productive
species can be obtained from the species-distribution profiles
of phylogenetic tree [19]. Almost 80% of the approved drugs
and 67% of the clinical-trial drugs concentrated in 17 and
30 drug-prolific families, respectively, including Fabid and
Malvid groups of the Rosidae subclass, the Lamiid and Cam-
panulid groups of the Asterid subclass, and the Ranunculales
order [24]. Eribulin mesylate is a structurally simplified
synthetic analogue of halichondrin B used for the treatment
of metastatic breast cancer, which is a natural product
isolated from the marine sponge Halichondria okadai, which
originates from a drug-productive family Halichondriidae
[25–27]. Taken together, these instances provide the basis to
screen for natural resources possessing AA activities through
phylogenetic tree analysis.
Thus, in this study, in order to examine the phylogenetic
tree and cold-hot nature of TCMM for identifying TCMMs
with potential AA properties, association rules mining and
phylogenetic tree construction methodologies were used
to investigate the association relationship and distribution
regularity of TCMMs with different nature possessing AA
properties.
2. Materials and Methods
2.1. Datasets Preparation. The cold-hot nature categoriza-
tion of 613 TCMMs related to 1,091 marine bioresources
species were retrieved from the “Chinese Marine Mate-
ria Medica” [22]. Latin name and taxonomy data of the
related bioresources were retrieved from the National Center
for Biotechnology Information (NCBI) Taxonomy Database
(https://www.ncbi.nlm.nih.gov/taxonomy) [28]. The 1,091
marine species were clustered into three groups: cold, hot,
and neutral.
The anticancer bioactivity information of each marine
bioresources species were retrieved from PubMed literature
database by using the following retrieval formula.
“Latin name of each marine bioresource species” [All
Fields] AND (anticancer [All Fields] OR antitumer [All
Fields] OR antitumor [All Fields]).
Each species was labeled with presence or absence of
anticancer bioactivity according to the retrieved results. All
the results were independently checked by two researchers, F.
X. and S. X.
2.2. Phylogenetic Tree Construction. The phylogenetic trees
were generated by using the NCBI taxonomy-based auto-
matic tree generator against known families in the Bacteria,
Viridiplantae, andMetazoa kingdoms or superkingdoms [24,
29].
First, TAX ID of each marine bioresources species were
retrieved from The NCBI Taxonomy System (https://www
.ncbi.nlm.nih.gov/taxonomy) [28].Then data of TAX IDwere
input to phylot web (http://phylot.biobyte.de/index.html) to
construct phylogenetic tree, and the visualization of the tree
was conducted in iTOL (version 3.3.2) and EvolView [19, 24,
30, 31]. Family or species names were labeled at branch ends.
Reported anticancer bioactivity clusters and different nature
were labeled or marked in the phylogenetic trees.
2.3. Association Rules Mining. The association relationship
between reported anticancer bioactivity and taxonomy or
nature types was mined by aRules package [32] based on the
R platform to elucidate the association rules.
An association rule is an implication of the form𝑋 ⇒ 𝑌,
where 𝑋 ⊂ 𝐼, 𝑌 ⊂ 𝐼, and 𝑋 ∩ 𝑌 = ⌀. The rule 𝑋 ⇒ 𝑌
holds in the database 𝐷 with confidence and support [33].
The support is a measure of the frequency of a rule, and
the confidence is a measure of the strength of the relation
between sets of items [34]. In this study, the cold-hot nature
and taxonomy data of TCMMswere taken as𝑋, while the AA
of eachTCMMwas regarded to𝑌; the association ruleswhose
confidence and support were larger than the set thresholds
(50.00% for confidence and 0.5% for support) were chosen as
strong association rules.
3. Results and Discussion
3.1. Cluster Pattern of Marine Organism from TCMMs with
Reported AA. In this study, 613 TCMMs originated from
1,091 species of marine organisms were screened for potential
AA properties (Table 1). Majority of the species (𝑛 = 870
of 1,091; 79.74%) were from Metazoa kingdom. Among the
1,091 species investigated, 194 species were reported to have
AA with nearly half of them (𝑛 = 92; 47.42%) from the
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Table 1: The distribution of marine species with AA in different kingdom or superkingdom.
Kingdom or Superkingdom# Number of species (%)a Number of species with AA (%)b
Metazoa 870 (79.74%) 92 (10.57%)
Viridiplantae 89 (8.16%) 45 (50.56%)
Others in Eukaryota# 123 (11.27%) 51 (41.46%)
Bacteria# 9 (0.82%) 6 (66.67%)
Total 1,091 (100%) 194 (17.78%)
aPercentage derived from division with the total number of species within all kingdom and superkingdom combined (𝑛 = 1,091).
bPercentage derived from division with the number of species within each corresponding kingdom or superkingdom.
# refers to superkingdom.
Metazoa kingdom.More than half of the interrogated species
within the Viridiplantae (green plants) kingdom (𝑛 = 45
of 89; 50.56%) and Bacteria superkingdom (𝑛 = 6 of 9;
66.67%) demonstrated AAs. This implies that the marine
species of TCMMs from Viridiplantae kingdom and Bacteria
superkingdom are more likely to possess AA.
Metazoa kingdom showed 61 AA families concentrated
in 38 clusters (Figure 1; Table S1 in Supplementary Mate-
rial available online at https://doi.org/10.1155/2017/4365715).
These families were present in seven of eight phylums known
to possess AAs (Table S2). Four phylums contained more
than ten AA species including 24 in Mollusca, 23 in Echin-
odermata, 22 in Chordata, and 10 in Cnidaria. There were
18 AA classes from 25 known classes of Metazoa (Table S3),
and three classes (Holothuroidea, Actinopteri, and Bivalvia)
contained more than ten AA species. Three orders (Aspi-
dochirotida, Veneroida, and Alcyonacea) contained more
than five AA species (Table S4).
This implies that TCMMs from Metazoa are potential
candidates for anticancer drug discovery. Diverse peptides
with a wide range of biological activities including antimicro-
bial and antitumoral have been isolated from different phyla
of Mollusca, Cnidaria, and Echinodermata [35]. Two novel
marine anticancer compounds, kahalalide F and ES285, have
been isolated from the Indopacific mollusc Elysia rufescens
and the North Atlantic mollusc Spisula polynyma, respec-
tively [36]. The phylum Cnidaria is unique such that practi-
cally all of itsmembers are toxic and containCnidarian toxins
which are a rich source of polypeptides with a wide variety
of biological activities including pore-forming cytolysins,
phospholipases, neurotoxins, and protease inhibitors [35].
These marine organisms could be an important source of
structurally bioactive secondary metabolites. There have
been 12 reported novel and highly potent antitumor natural
products derived from seven species of cnidarians of marine
origin [37].
Figure 2 presents the distribution of marine families with
AA in phylogenetic tree of Viridiplantae kingdom, Eukaryota
superkingdom, and Bacteria superkingdom. A total of 52 AA
families were concentrated in 18 clusters (Figure 2; Table S5).
These families were distributed in five AA phylums (Table S6)
in which Streptophyta phylums of Viridiplantae contained
35 AA species. There were two classes from the Eukaryota
superkingdom containing more than 20 AA species (Table
S7), the Florideophyceae (24 AA species) and Phaeophyceae
(23 AA species). One order (Fucales) contained more than
ten AA species (Table S8).
Compared with Figure 1, Figure 2 showed more concen-
trated anticancer family clusters in Bacteria and Eukaryota
superkingdom than Metazoa kingdom. Bacteria have widely
contributed to some of the most useful chemotherapeutic
drugs [38], while marine cyanobacteria contain antipro-
liferative properties, yielding several potent inhibitors of
malignancies [39]. All of the six AA species of TCMMs from
Bacteria superkingdom are of Cyanobacteria phylum.
Viridiplantae (green plants) are an ancient group of
eukaryotes comprising of two main clades: the Chlorophyta
and the Streptophyta. The former consists of a wide diversity
of green algae while the latter consists of freshwater green
algae and terrestrial plants [40]. There are four phyla of
algae including red algae (Florideophyceae), brown algae
(Phaeophyceae), green algae (Chlorophyta), and diatom
(Bacillariophyceae) and two phyla of plants from coastal
wetlands including Pteridophyta and Angiospermae [10].
Marine plants serve as main sources of potential anticancer
agents [38].
3.2. Cold-Hot Nature Distribution of Marine Organism from
TCMMs with Reported AA. Within the 1,091 marine organ-
isms, 380 can be grouped into TCMMs with cold nature,
233 with hot nature, and 366 with neutral nature (Table 2).
More than half of AA species were from the cold group
(𝑛 = 51.03%), followed by the neutral (25.26%) and hot group
(12.37%).
It was reported that basic pharmacological effects of
herbals with cold nature are antibacterial, anti-inflammatory,
antitumor, antipyretic, diuretic, lowering blood pressure,
sedation, and analgesic [41]. Most frequently used TCMMs
are generally of cold nature [20]. Studies have shown that salty
flavor and cold nature (such as Sargassum and Laminariae
Thallus) are representative of TCMMs [10, 20]. In terms
of medicinal effects, the most representative efficacies of
TCMMs with salty-cold flavor and nature (e.g., Sargassum,
Laminariae Thallus, Ostreae Concha, and Meretricis Concha)
include softening hard mass and removing stasis to treat
cancers [10]. This might serve as an explanation, at least
partially, as to why AA species are often from the cold group.
3.3. The Association Rules and Phylogenetic Tree of Marine
Organisms. The association rules mining resulted in 12
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Numbers of all species in the family 
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Metazoa
Figure 1:The distribution of marine anticancer activity families (green background color) phylogenetic tree of Metazoa kingdom.The family
names are provided at branch ends, which can be viewed more clearly by enlarging the figure in the electronic version.The length of the blue
and green bar outside the circle represents the number of all species and the AA species, respectively, in the family.
screened rules (Table 3). There were 11 rules with single
item and one with double items. In the single item rules,
one was of superkingdom (Bacteria with confidence of
66.67%) and one was associated with Streptophyta phylum,
while two were related to Holothuroidea and Phaeophyceae
classes. The Malpighiales order and Rhizophoraceae family
showed strong association with AA with confidences of
87.50% and 85.71%, respectively.The double items of cold and
Viridiplantae kingdom also showed strong association with
AA, implying that the species of TCMMs with cold nature
from Viridiplantae kingdom tend to have AA.
Figure 3 shows the cluster pattern of marine AA fam-
ilies, in the phylogenetic tree of marine organisms, tended
to cluster with cold nature TCMMs. In contrast, few of
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Figure 2:The distribution of marine families with AA in phylogenetic tree of Viridiplantae kingdom, Eukaryota superkingdom, and Bacteria
superkingdom. Coloring and labeling schemes are as described in Figure 1.
the AAs-containing families clustered with hot and neutral
nature TCMMs.The screened association rules labeled at the
corresponding branch collected at three species groups (from
superkingdom to genus) in the phylogenetic tree. The cluster
pattern (Figure 3) contained three major groups: (1) the first
group consisting of Bacteria superkingdom, Phaeophyceae
class, Fucales order, Sargassaceae family, and Sargassum
genus; (2) the second group consisting of Viridiplantae
kingdom, Streptophyta phylum, Malpighiales class, and Rhi-
zophoraceae family; (3) the third group comprising three
levels of Holothuroidea class, Aspidochirotida order, and
Holothuria genus at the same branch.
The results above suggest that certain species of TCMMs
with closer taxonomic relationship are more likely to have
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Table 2: The distribution of marine organisms with AA in different nature categories.
Nature Number of species (%)a Number of species with AA (%)b
Cold 380 (34.83) 99 (26.05)
Hot 233 (21.36) 24 (10.30)
Neutral 366 (33.55) 49 (13.39)
None 112 (10.27) 22 (19.64)
Total 1,091 (100.00) 194 (17.78)
aPercentage derived from division with the total number of species within all different natures combined (𝑛 = 1,091).
bPercentage derived from division with the number of species within each corresponding nature.
Table 3: The results of association rules mining (support > 0.5%, confidence > 50%, lift > 2).
Rule ID Single or double items Taxonomic rank Rules Support Confidence Lift
1 Single item Super kingdom {𝐵𝑎𝑐𝑡𝑒𝑟𝑖𝑎} ⇒ {anticancer} 0.55% 66.67% 3.75
2 Single item Phylum {𝑆𝑡𝑟𝑒𝑝𝑡𝑜𝑝ℎ𝑦𝑡𝑎} ⇒ {anticancer} 3.21% 52.24% 2.94
3 Single item Class {𝑃ℎ𝑎𝑒𝑜𝑝ℎ𝑦𝑐𝑒𝑎𝑒} ⇒ {anticancer} 2.20% 63.16% 3.55
4 {𝐻𝑜𝑙𝑜𝑡ℎ𝑢𝑟𝑜𝑖𝑑𝑒𝑎} ⇒ {anticancer} 1.28% 51.85% 2.92
5
Single item Order
{𝑀𝑎𝑙𝑝𝑖𝑔ℎ𝑖𝑎𝑙𝑒𝑠} ⇒ {anticancer} 0.64% 87.50% 4.92
6 {𝐹𝑢𝑐𝑎𝑙𝑒𝑠} ⇒ {anticancer} 1.19% 65.00% 3.66
7 {𝐴𝑠𝑝𝑖𝑑𝑜𝑐ℎ𝑖𝑟𝑜𝑡𝑖𝑑𝑎} ⇒ {anticancer} 1.10% 52.17% 2.93
8 Single item Family {𝑅ℎ𝑖𝑧𝑜𝑝ℎ𝑜𝑟𝑎𝑐𝑒𝑎𝑒} ⇒ {anticancer} 0.55% 85.71% 4.82
9 {𝑆𝑎𝑟𝑔𝑎𝑠𝑠𝑎𝑐𝑒𝑎𝑒} ⇒ {anticancer} 1.19% 68.42% 3.85
10 Single item Genus {𝑆𝑎𝑟𝑔𝑎𝑠𝑠𝑢𝑚} ⇒ {anticancer} 1.01% 68.75% 3.87
11 {𝐻𝑜𝑙𝑜𝑡ℎ𝑢𝑟𝑖𝑎} ⇒ {anticancer} 0.73% 61.54% 3.46
12 Double items Nature & kingdom {cold, 𝑉𝑖𝑟𝑖𝑑𝑖𝑝𝑙𝑎𝑛𝑡𝑎𝑒} ⇒ {anticancer} 2.57% 56.00% 3.15
AA. The AA of marine organisms is mostly based on the
secondary metabolites of each species [42, 43]. The distribu-
tion of secondary metabolites has some value for taxonomy
[44]. Chemical structure of secondary metabolites forms the
molecular basis for its bioactivity [45], and marine natural
products are important sources of chemical scaffolds [46].
Natural products frommarine species with closer taxonomic
relationship contain similar scaffolds and bioactivities [47].
For instance, the marine organisms Sargassum fusiforme,
Sargassum hemiphyllum, Sargassum pallidum, Sargassum car-
pophyllum, Sargassum horneri, and Sargassum thunbergii are
from the Sargassaceae family that form the TCMM seaweed
(known as “haizao” in Chinese or海藻) with cold nature. All
of the Sargassum seaweed possessed phytosterols compounds
with the same scaffold (compounds 1–5 in Table 4) or
similar structure (compounds 6 inTable 4) containing similar
anticancer bioactivity.
In addition to the grouped species of TCMMs with closer
taxonomic relationship, TCMM species with cold nature
from Viridiplantae kingdom also showed a tendency for
AA with confidence of 56%. As discussed above, marine
plants contain potential anticancer agents and cold nature
TCMMs render softening of hard mass and stasis removal.
Hence, the species (e.g.,Ulva pertusa [48]) with combination
of Viridiplantae kingdom and cold nature are more likely
to demonstrate AA. For example, Ulva pertusa from the
Ulvaceae family of Viridiplantae kingdom was used as classic
TCMM with cold nature to treat thyroid neoplasm from
Tang dynasty and recorded in the herbal book of “Bencao
Shiyi (Supplement to Materia Medica,本草拾遗)” [22]. It is
reported thatUlva pertusa showed antitumor activity against
Meth-A fibrosarcoma by intraperitoneal administration of
50mg/kg daily for seven days [49].
Nonetheless, we acknowledge limitations of the study
as follows: (1) the studies included in the phylogenetic tree
analysis took into account results from in vitro investigations.
However, in vitro studies have remained the prerequisite
before a candidate compound is tested further in in vivo
or human trials settings, and excluding results from in
vitro studies could significantly reduce the sensitivity of our
analysis; (2) this study represented TCMMs originated from
species of marine organisms for potential AA properties
available currently and several more are being actively dis-
covered.
Our previous study showed that the TCMM from the
organisms in the same familymayhave the samenature, while
marine plants such as Chlorophyta, Florideophyceae, and
Phaeophyceae were associated with cold nature, and marine
animals including Decapoda, Malacostraca, and Arthropoda
contained close relationship with hot nature [19]. The differ-
ent nature types seem to affect different biological processes
based on the pluralistic character of molecular structure
[50]. For distribution of secondary metabolites from marine
species with closer taxonomic relationship, they contain sim-
ilar scaffolds and bioactivities [47]. Marine algae associated
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{Bacteria}⇒{Anticancer}
{Phaeophyceae}⇒{Anticancer}
{Sargassaceae}⇒{Anticancer}
{Fucales}⇒{Anticancer}
{Sargassum}⇒{Anticancer}
{Rhizophoraceae}⇒{Anticancer}
{Malpighiales}⇒{Anticancer}
{Aspidochirotida}⇒{Anticancer}
{Holothuroidea}⇒{Anticancer}
{Holothuria}⇒{Anticancer}
{Streptophyta}⇒{anticancer}
{Cold, Viridiplantae}⇒{anticancer}
Cold
Hot
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ABC With anticancer activity
Figure 3: The distribution of marine AA species (green background) in the phylogenetic tree of marine organisms. The cold-hot nature of
each species was labeled outside of the circle by different colors.The length of the bar represents the degree of nature of TCMMs.The screened
association rules were labeled at the corresponding branch (the branches marked with different color). The names of species of the marine
organisms of TCMMs are provided at branch ends, which can be viewed more clearly by enlarging the figure in the electronic version.
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Table 4: Anticancer compounds from species of Sargassaceae family of the TCMM Seaweed (Haizao,海藻).
ID Name Structure Species AA
Scaffold R
1 Fucosterol [11–16]
R
HO
(1) Sargassum fusiforme
(2) Sargassum
hemiphyllum
(3) Sargassum pallidum
(4) Sargassum
carpophyllum
(5) Sargassum horneri
(6) Sargassum thunbergii
(1) Induce the
deformation
activity of rice blast
fungus
(2) Inhibit the
growth of P-388,
T47D, and HT29
cell lines.
2 Sargasterol [13, 14]
R
HO OH
(1) Sargassum fusiforme
(2) Sargassum
hemiphyllum
(3) Sargassum pallidum
(4) Sargassum
carpophyllum
Induce the
deformation
activity of rice blast
fungus
3
24- Hydrogen
peroxide based
-24- vinyl
cholesterol [13]
R
HO OOH
(1) Sargassum fusiforme
(2) Sargassum
hemiphyllum
(3) Sargassum
carpophyllum
(1) Induce the
deformation
activity of rice blast
fungus
(2) Inhibit the
growth of HL-60
cell line.
4
24S, 28S- epoxy
-24- ethyl
cholesterol [13]
R
HO
O
H
(1) Sargassum fusiforme
(2) Sargassum
carpophyllum
(1) Induce the
deformation
activity of rice blast
fungus
(2) Inhibit the
growth of MCF-7,
HCT-8, 1A9, HOS,
and PC-3 cell lines.
5 Cholesterol -24-ketone [13]
R
HO
O
Sargassum carpophyllum
Induce the
deformation
activity of rice blast
fungus
6
24-Ethylcholest-4-
en-3,6-dione
[13]
OO
Sargassum carpophyllum
(1) Induce the
deformation
activity of rice blast
fungus
(2) Inhibit the
growth of P-388
cell line.
with cold nature such as Chlorophyta, Florideophyceae, and
Phaeophyceae contain antitumor properties [51].
4. Conclusions
Our analysis demonstrated that potential AA derived from
Metazoa or Viridiplantae species with cold nature tended to
have close taxonomic relationship than distantly distributed
in phylogenetic tree. The clustered patterns with mined
association rules presented in this work provide information
pertaining to the groups of specieswith anticancer properties.
Moreover, we have shown that phylogenetic tree analysis can
be utilized to shortlist plant or animal species that possess
potential AA. Future bioprospecting studies on TCMMs are
thus warranted with aims of producing novel anticancer
drugs.
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